Sword’s core intellectual property enables the company to provide Pharma with Build-to-Order tests that meet their exact needs in a matter of weeks.
Sword’s patented technology enables rapid production of "Build-to-Order" tests that speed drug development and seamlessly integrate with 50-year-old technology in use today. Our tests do not require changes to test instruments or protocols. Customers include BMS, Eli Lilly, Novartis, TEVA and Sanofi Genzyme, with drug development efforts targeting many diseases. Sword has Master Services Agreements with its first two large pharma companies.